1. The Proportion of Long-term Response to Anti-N IgG Antibody after 12 Months for COVID-19 Subclinical Infections and a Longitudinal Survey for COVID-19 Subclinical Infections in 2021
- Author
-
Ikuro, Matsuba, Tetsuo, Takuma, Nobuo, Hatori, Masahiko, Takai, Yoshiyuki, Watanabe, Nobukazu, Takada, Satoru, Kishi, Yoko, Matsuzawa, Tetsuo, Nishikawa, Tomoyuki, Kunishima, Hisakazu, Degawa, Masanori, Nishikawa, Yoshiaki, Ono, Masaaki, Miyakawa, Yutaka, Hatori, and Akira, Kanamori
- Subjects
Angiotensin Receptor Antagonists ,SARS-CoV-2 ,Immunoglobulin G ,Internal Medicine ,COVID-19 ,Coronavirus Nucleocapsid Proteins ,Humans ,General Medicine ,Antibodies, Viral ,Phosphoproteins ,Asymptomatic Infections - Abstract
Objective To examine the continuation of antibody prevalence status after 12 months and background factors in antibody-positive subjects following asymptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods We initially determined the SARS-CoV-2 anti-nucleocapsid protein immunoglobulin G (anti-N IgG) antibody prevalence in 1,603 patients, doctors, and nurses at 65 medical institutions in Kanagawa Prefecture, Japan. We then obtained consent from 33 of the 39 subjects who tested positive and performed follow-up for 12 months. Results Follow-up for up to 12 months showed that a long-term response of the anti-N IgG antibody could be detected in 6 of the 33 participants (18.2%). The proportions with hypertension, using an angiotensin-receptor blocker, and without a drinking habit were higher among the participants with a long-term anti-N IgG antibody response for up to 12 months than among those without a long-term antibody response. Conclusions The proportion of individuals with subclinical COVID-19 who continuously had a positive result for the anti-N IgG antibody at 12 months was low.
- Published
- 2022
- Full Text
- View/download PDF